Detalhe da pesquisa
1.
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
Ann Rheum Dis
; 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641124
2.
Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients.
Liver Int
; 42(12): 2674-2682, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152268
3.
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.
J Infect Dis
; 218(9): 1480-1484, 2018 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29893893
4.
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.
Antimicrob Agents Chemother
; 61(1)2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27799203
5.
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
Antimicrob Agents Chemother
; 61(7)2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28507108
6.
Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.
Gastroenterology
; 160(7): 2595-2598.e3, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662385
7.
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
J Antimicrob Chemother
; 72(3): 820-828, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27999038
8.
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases.
Clin Transl Gastroenterol
; 14(4): e00560, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36573890
9.
Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.
J Crohns Colitis
; 17(10): 1689-1697, 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129565
10.
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial.
J Allergy Clin Immunol Glob
; 2(4): 100140, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37781656
11.
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Eur J Haematol
; 89(1): 47-52, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22324351
12.
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Lancet Gastroenterol Hepatol
; 7(11): 1024-1035, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075249
13.
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
Hepatol Commun
; 5(1): 97-111, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33437904
14.
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Am J Hematol
; 85(12): 921-5, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21108325
15.
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.
J Virus Erad
; 5(1): 10-22, 2019 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30800421
16.
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
PLoS One
; 6(10): e26375, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22031830
17.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Arthritis Res Ther
; 11(3): R95, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19549290